| Trial ID # | NCT04781088 |
| Phase | II |
| Drug Class | Angiogenesis Inhibitors: Multi-targeted RTK |
| Drug Name | Lenvatinib |
| Alternate Drug Names | MK-7902, Lenvima, ER-203492-00, E7080 |
| Drugs in Trial | Lenvatinib, Paclitaxel, Pembrolizumab |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 24 ovarian, median 2 prior therapies (1-3) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DoR, PFS, evaluated per RECIST |
| Efficacy | ORR: 47% (2CR, 9PR, n=24) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Encouraging activity is seen in ovarian cancer; the regimen is tolerable with manageable side effects; however, a high number of patients discontinued treatment for toxicity per protocol or patient preference |
| Reference | Backer FJ et al. A phase II study of weekly paclitaxel, lenvatinib and pembrolizumab among patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer. SGO (2024) |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.